Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Dermatology

Free Subscription Articles published in Cancer Res Retrieve available abstracts of 148 articles: HTML format

Single Articles

June 2026
1. HOU X, Chen M, Guo X, Xie Y, et al
   The SDC1-ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance.
   Cancer Res. 2026;86:3005-3025.
   PubMed     Abstract available
   
   
   
2. AMBROSINI G, Do C, Tycko B, Realubit RB, et al
   Editor's Note: Inhibition of NF-kappaB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma.
   Cancer Res. 2026;86:3092.
   PubMed    
   
   
   
3. YEVDASH JI, Robinson D, Moore R, Li Z, et al
   GNAQ Induces Melanomagenesis in Mitfa-Independent Melanocyte Progenitors in a Zebrafish Model of Uveal Melanoma.
   Cancer Res. 2026 Jun 10. doi: 10.1158/0008-5472.CAN-25-5299.
   PubMed     Abstract available
   
   
   
4. KREUGER IZM, Merkus VA, de Haan S, Schrader AMR, et al
   Spatial Analysis Reveals Gene Expression and Microenvironmental Changes in the Transition of Nevus to Melanoma.
   Cancer Res. 2026 Jun 8. doi: 10.1158/0008-5472.CAN-25-2934.
   PubMed     Abstract available
   
   
   May 2026
5. SRIRAMAREDDY S, Siddarajappa N, Park JS, Nguyen T, et al
   GDF15 Reprograms the Microenvironment to Drive Liver Metastasis of Uveal Melanoma.
   Cancer Res. 2026 May 28. doi: 10.1158/0008-5472.CAN-25-0536.
   PubMed     Abstract available
   
   
   
6. FOTH M, Kim W, O'Toole K, Murphy B, et al
   Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma.
   Cancer Res. 2026 May 22. doi: 10.1158/0008-5472.CAN-26-1313.
   PubMed     Abstract available
   
   
   
7. YOO JY, Akter S, Zuo Q, Rilloraza M, et al
   In Silico Reconstruction of Primary and Metastatic Tumor Architecture Using Geographic Information System-Augmented Spatial Transcriptomics.
   Cancer Res. 2026;86:2555-2568.
   PubMed     Abstract available
   
   
   
8. FLAHERTY RL, Hughes F, Sflomos G, Ronchi C, et al
   LOX Inhibition Disrupts a Collagen-Integrin-MYC Axis to Suppress Progression of Invasive Lobular Carcinoma.
   Cancer Res. 2026;86:2487-2507.
   PubMed     Abstract available
   
   
   April 2026
9. YOUNG RG, Esquea EM, Ciraku L, Merzy J, et al
   ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis.
   Cancer Res. 2026 Apr 22. doi: 10.1158/0008-5472.CAN-25-3006.
   PubMed     Abstract available
   
   
   
10. SHER EF, Fujihara KM, Tao A, Sastourne-Haletou P, et al
    Targeting DNA Polymerase Epsilon Induces Tumor Clearance and Activates an NF-kappaB-Mediated Inflammatory Response in Triple Negative Breast Cancer.
    Cancer Res. 2026 Apr 21. doi: 10.1158/0008-5472.CAN-25-2217.
    PubMed     Abstract available
    
    
    
11. WONG H, Korsakova A, Wu AJ, Kularatnarajah L, et al
    An Analytical Framework Characterizes the Biological Processes that Shape Copy Number-Based Genome Instability Patterns in Breast Cancer.
    Cancer Res. 2026 Apr 9. doi: 10.1158/0008-5472.CAN-25-2569.
    PubMed     Abstract available
    
    
    
12. TANKKA AT, Zhang Y, Einstein JM, Zhou CJ, et al
    Integrative CRISPR Screening and RNA Analyses Discover an Essential Role for PUF60 Interactions with 3' Splice Sites in Cancer Progression.
    Cancer Res. 2026;86:1586-1604.
    PubMed     Abstract available
    
    
    March 2026
13. GAO A, Khatri PH, Ma G, Liu P, et al
    Integrated Multi-omic Profiling Identifies BRD8/EP400 as a Pivotal Chromatin Module Mediating Anti-HER2 Response in HR+/HER2+ Breast Cancer.
    Cancer Res. 2026 Mar 26. doi: 10.1158/0008-5472.CAN-25-4701.
    PubMed     Abstract available
    
    
    
14. XING Y, Tan Y, Hu B, Zhang H, et al
    PAK5-Mediated Suppression of beta-Hydroxybutyrate Production Promotes Breast Cancer Metastasis and Can Be Overcome with Ketogenic Diet.
    Cancer Res. 2026;86:1435-1450.
    PubMed     Abstract available
    
    
    
15. HU J, Zhang B, Chen J, Huang G, et al
    Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells.
    Cancer Res. 2026;86:1351-1371.
    PubMed     Abstract available
    
    
    February 2026
16. KRANTZ S, Bell BA, Lund K, Salinas Parra N, et al
    Dissection of Galphas and Hedgehog Signaling Cross-talk Reveals Therapeutic Opportunities to Target Hedgehog-Dependent Tumors.
    Cancer Res. 2026;86:940-953.
    PubMed     Abstract available
    
    
    
17. RONDEAU V, Bansal S, Buttigieg MM, Zeng AGX, et al
    Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation.
    Cancer Res. 2026;86:845-857.
    PubMed     Abstract available
    
    
    
18. NANDI D, Parida S, Verma D, Foley JR, et al
    Spermine Oxidase Serves as a Key Functional Node in Microbial Dysbiosis-Induced Breast Carcinogenesis.
    Cancer Res. 2026 Feb 16:10.1158/0008-5472.CAN-25-2086.
    PubMed     Abstract available
    
    
    
19. LUO Z, Li K, Yu Y, Liu Y, et al
    LDHB Deficiency in Fibroblasts Induces Lactate-Mediated Inflammatory Reprogramming that Promotes Breast Cancer Metastasis.
    Cancer Res. 2026 Feb 13. doi: 10.1158/0008-5472.CAN-25-2792.
    PubMed     Abstract available
    
    
    
20. ORTEGA-ALVAREZ D, Tebar-Garcia D, Casado-Pelaez M, Olivares-Osuna D, et al
    Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies.
    Cancer Res. 2026 Feb 11. doi: 10.1158/0008-5472.CAN-24-2758.
    PubMed     Abstract available
    
    
    
21. XU X, Liu X, Jarajapu V, Neelature Sriramareddy S, et al
    A Multi-Step Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma.
    Cancer Res. 2026 Feb 9. doi: 10.1158/0008-5472.CAN-25-2684.
    PubMed     Abstract available
    
    
    
22. SINGHAL S, Li C, Aukerman A, Carriere M, et al
    Topology-Based Biomarkers Accurately Predict Breast Cancer Outcome and Survival.
    Cancer Res. 2026 Feb 9. doi: 10.1158/0008-5472.CAN-25-1216.
    PubMed     Abstract available
    
    
    
23. BERENS EB, Khou S, Huang ET, Hoffman A, et al
    Neoplastic Immune Mimicry Potentiates Breast Tumor Progression.
    Cancer Res. 2026;86:587-603.
    PubMed     Abstract available
    
    
    January 2026
24. CHEN S, Chang C, Liu X, Wang R, et al
    ACSL5 Mediates Adaptation to the Palmitic Acid-Enriched Pulmonary Microenvironment to Enhance Metastatic Breast Cancer Cell Survival and Lung Metastasis.
    Cancer Res. 2026 Jan 22. doi: 10.1158/0008-5472.CAN-25-0866.
    PubMed     Abstract available
    
    
    
25. CHEN PY, Bollag G
    Overcoming the Limits of Inhibition: Mutant-Selective BRAF Degraders.
    Cancer Res. 2026;86:289-291.
    PubMed     Abstract available
    
    
    
26. KREGER BT, Liang Y, Reilly NM, Spears ME, et al
    CFT1946 Is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader That Overcomes BRAF Inhibitor Resistance.
    Cancer Res. 2026;86:438-452.
    PubMed     Abstract available
    
    
    
27. SOTTNIK JL, Shackleford MT, Nesiba CS, Richer AL, et al
    Altered MDC1 Interactions and Dysfunctional DNA Repair in Lobular Breast Cancer Confers Sensitivity to PARP Inhibition.
    Cancer Res. 2026 Jan 9. doi: 10.1158/0008-5472.CAN-25-1217.
    PubMed     Abstract available
    
    
    
28. HERZOG SK, Stevens JH, Gu G, Grimm SL, et al
    Defective DNA Damage Response is a Targetable Therapeutic Vulnerability in ESR1 Mutant Breast Cancer.
    Cancer Res. 2026 Jan 7. doi: 10.1158/0008-5472.CAN-24-3891.
    PubMed     Abstract available
    
    
    
29. PERURENA N, Watanabe M, Schade AE, Brown W, et al
    EZH2 Inhibitors Sensitize Breast Cancer to HER2 Kinase Inhibitors through Cooperative Effects on YAP and Pro-apoptotic Regulators.
    Cancer Res. 2026 Jan 5. doi: 10.1158/0008-5472.CAN-24-3113.
    PubMed     Abstract available
    
    
    December 2025
30. RYSER MD, Greenwald MA, Monyak D, Sorribes IC, et al
    Spatially Discontinuous Mutation Topographies in Ductal Carcinoma In Situ Reveal Noncompetitive Growth Dynamics.
    Cancer Res. 2025;85:5084-5097.
    PubMed     Abstract available
    
    
    
31. XIA Z, Liu W, Guo D, Chen L, et al
    circADAMTS12 Inhibits the Antitumor Activity of Microglia to Enable Metastatic Colonization in the Brain.
    Cancer Res. 2025;85:4977-4994.
    PubMed     Abstract available
    
    
    
32. CHENG Y, Huang G, Liu X, Wu C, et al
    Fusion of Tumor Cells with Lipid-Associated Macrophages Drives Metastatic Progression of Breast Cancer.
    Cancer Res. 2025 Dec 4:OF1-OF18. doi: 10.1158/0008-5472.CAN-25-0261.
    PubMed     Abstract available
    
    
    
33. ARNOUK SM, Kancheva D, Van Damme H, Courtoy GE, et al
    Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti-PD-1 Immunotherapy.
    Cancer Res. 2025;85:4681-4700.
    PubMed     Abstract available
    
    
    November 2025
34. MOHAMMAD MIRZAEI N, Hur C, Terry MB, Dalerba P, et al
    Modeling Early-Onset Cancer Kinetics Reveals Changes in Underlying Risk and the Impact of Population Screening.
    Cancer Res. 2025;85:4558-4570.
    PubMed     Abstract available
    
    
    
35. HOFER I, Kieffer Y, Mencattini A, Croizer H, et al
    An Extracellular Matrix-Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation.
    Cancer Res. 2025 Nov 12. doi: 10.1158/0008-5472.CAN-25-0966.
    PubMed     Abstract available
    
    
    
36. YIN S, Liu Y, Guan X, Wang X, et al
    Tetraspanin 13 Enhances Immune Evasion in Breast Cancer by Promoting MHC-I Degradation.
    Cancer Res. 2025 Nov 11. doi: 10.1158/0008-5472.CAN-25-1223.
    PubMed     Abstract available
    
    
    
37. BONECHI F, Bacci M, Lorito N, Smiriglia A, et al
    ESR1 Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer.
    Cancer Res. 2025 Nov 7. doi: 10.1158/0008-5472.CAN-25-1339.
    PubMed     Abstract available
    
    
    October 2025
38. CHENOWETH AM, Cheung A, Chauhan J, Adams R, et al
    An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer.
    Cancer Res. 2025 Oct 23:OF1-OF20. doi: 10.1158/0008-5472.CAN-24-3174.
    PubMed     Abstract available
    
    
    
39. EL LAITHY Y, Abreu De Oliveira WA, Pabba A, Qualizza A, et al
    Chemotherapy-Treated Breast Cancer Cells Activate the WNT Signaling Pathway to Enter a Diapause-Like Early Persister State.
    Cancer Res. 2025 Oct 21. doi: 10.1158/0008-5472.CAN-24-4165.
    PubMed     Abstract available
    
    
    September 2025
40. LIU J, Fang F, Yuan W, Chen T, et al
    Integrating Circulating Tumor DNA Dynamics and Sequential Organoid Drug Screening Enhances Breast Cancer Treatment Efficacy.
    Cancer Res. 2025 Sep 24. doi: 10.1158/0008-5472.CAN-25-0608.
    PubMed     Abstract available
    
    
    
41. LIU P, Zheng J, Ma W, Lu J, et al
    Stress Promotes Lung Metastasis in Breast Cancer by Altering Neutrophil Differentiation.
    Cancer Res. 2025 Sep 24. doi: 10.1158/0008-5472.CAN-25-1763.
    PubMed     Abstract available
    
    
    
42. KHAN F, Petrosyan E, Liu Y, Bahrami A, et al
    Microglial TBK1 Signaling Promotes Breast Cancer Brain Metastasis.
    Cancer Res. 2025 Sep 18. doi: 10.1158/0008-5472.CAN-25-1791.
    PubMed     Abstract available
    
    
    
43. TAO JJ, Vasan N
    A New VISTA in Intracellular Checkpoint Signaling in Triple-Negative Breast Cancer.
    Cancer Res. 2025;85:3371-3372.
    PubMed     Abstract available
    
    
    
44. ZHAO Y, Andoh T, Charles F, Reddy P, et al
    A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression.
    Cancer Res. 2025;85:3399-3415.
    PubMed     Abstract available
    
    
    
45. MOLDRUP RIJ, Terp MG, Jakobsen ST, Ravnsborg T, et al
    SWI/SNF Functions as a Gatekeeper of Enhancer Chromatin Access to Control Progression of Mesenchymal Triple-Negative Breast Cancer.
    Cancer Res. 2025 Sep 10. doi: 10.1158/0008-5472.CAN-24-1660.
    PubMed     Abstract available
    
    
    
46. AVELLINO A, Jiang X, Lee M, Yu J, et al
    An Olive Oil-Based High-Fat Diet Promotes Obesity-Driven Metastasis of Triple-Negative Breast Cancer.
    Cancer Res. 2025 Sep 5. doi: 10.1158/0008-5472.CAN-25-0822.
    PubMed     Abstract available
    
    
    August 2025
47. FLEM-KARLSEN K, Talty R, McGeary MK, Park K, et al
    Cytotoxic CD8+ T Cells Downregulate GPX4 to Promote Ferroptosis in Melanoma that Drives Antitumor Immunity.
    Cancer Res. 2025 Aug 19. doi: 10.1158/0008-5472.CAN-24-1952.
    PubMed     Abstract available
    
    
    
48. ZHU XZ, Zhang HY, Zhou YF, Chen YY, et al
    Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2- Breast Cancer.
    Cancer Res. 2025 Aug 18. doi: 10.1158/0008-5472.CAN-24-5002.
    PubMed     Abstract available
    
    
    
49. SHAN JL, Zhang KM, Zhong WQ, Yang XY, et al
    Reactivating cGAS-STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors.
    Cancer Res. 2025;85:3015-3031.
    PubMed     Abstract available
    
    
    
50. RINKENBAUGH AL, Qi Y, Cai S, Shao J, et al
    An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naive and Longitudinal Samples During Neoadjuvant Chemotherapy.
    Cancer Res. 2025 Aug 13. doi: 10.1158/0008-5472.CAN-24-5023.
    PubMed     Abstract available
    
    
    
51. QI Z, He L, Xu Z, Luo X, et al
    PCBP2 Mediates Olaparib Resistance in Breast Cancer by Inhibiting m6A Methylation to Stabilize PARP1 mRNA.
    Cancer Res. 2025 Aug 7. doi: 10.1158/0008-5472.CAN-24-4751.
    PubMed     Abstract available
    
    
    
52. AMBROSINI G, Do C, Tycko B, Realubit RB, et al
    Correction: Inhibition of NF-kappaB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma.
    Cancer Res. 2025;85:2954.
    PubMed    
    
    
    
53. GONG H, Li Y, Yang W, Xie Z, et al
    PRODH2-Mediated Metabolism in the Bone Microenvironment Promotes Breast Cancer Metastasis.
    Cancer Res. 2025 Aug 1. doi: 10.1158/0008-5472.CAN-24-4391.
    PubMed     Abstract available
    
    
    July 2025
54. CAKSA S, Purwin TJ, Erkes DA, DeRosa KM, et al
    Elevated Transglutaminase-2 in SOX10-Deficient Melanoma Promotes Tumor Onset and Decreases Intratumoral CD4+ T Cells.
    Cancer Res. 2025 Jul 31. doi: 10.1158/0008-5472.CAN-24-3267.
    PubMed     Abstract available
    
    
    
55. LAIGHT BJ, Harper D, Dmytryk N, Zhang CS, et al
    Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy.
    Cancer Res. 2025;85:2643-2658.
    PubMed     Abstract available
    
    
    June 2025
56. QIN X, Strand SH, Lee MR, Saraswathibhatla A, et al
    Single-Cell Expression Analysis of Ductal Carcinoma In Situ Identifies Complex Genotypic-Phenotypic Relationships Altering Epithelial Composition.
    Cancer Res. 2025;85:2302-2319.
    PubMed     Abstract available
    
    
    
57. IBRAHIM M, Illa-Bochaca I, Jour G, Vega-Saenz de Miera E, et al
    NF1 Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in NF1 Mutant Melanoma.
    Cancer Res. 2025 Jun 10. doi: 10.1158/0008-5472.CAN-24-3904.
    PubMed     Abstract available
    
    
    
58. XIAO Y, Elmasry M, Bai JDK, Chen A, et al
    Eco-Evolutionary Guided Pathomic Analysis Detects Biomarkers to Predict Ductal Carcinoma In Situ Upstaging.
    Cancer Res. 2025;85:2537-2547.
    PubMed     Abstract available
    
    
    May 2025
59. KIM EJ, Wang Y, Chen YL, Ma M, et al
    CARM1-mediated MAP2K4 methylation potentiates the oncogenic functions of MAP2K4 and constitutes a targetable dependency in triple-negative breast cancer.
    Cancer Res. 2025 May 29. doi: 10.1158/0008-5472.CAN-24-3476.
    PubMed     Abstract available
    
    
    
60. GOHARI Z, Stojanovic L, Rassool FV
    Combining STING Agonists with PARP Inhibitors Mounts an NK-Dependent Defense against Therapy-Resistant Breast Cancer.
    Cancer Res. 2025;85:1747-1749.
    PubMed     Abstract available
    
    
    
61. ELKHOLI IE, Robert A, Malouf C, Wu JL, et al
    Targeting the Dependence on PIK3C3-mTORC1 Signaling in Dormancy-Prone Breast Cancer Cells Blunts Metastasis Initiation.
    Cancer Res. 2025 May 15:OF1-OF20. doi: 10.1158/0008-5472.CAN-23-2654.
    PubMed     Abstract available
    
    
    
62. ABBASI A, Steele CD, Bergstrom EN, Khandekar A, et al
    HRProfiler Detects Homologous Recombination Deficiency in Breast and Ovarian Cancers Using Whole-Genome and Whole-Exome Sequencing Data.
    Cancer Res. 2025 May 6. doi: 10.1158/0008-5472.CAN-24-2639.
    PubMed     Abstract available
    
    
    
63. GADAL S, Boyer JA, Roy SF, Outmezguine NA, et al
    Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration.
    Cancer Res. 2025;85:1611-1627.
    PubMed     Abstract available
    
    
    April 2025
64. LUTZ C, Chao X, de Klein B, Bhin J, et al
    Large-Scale Characterization of Orthotopic Cell Line-Derived Xenografts Identifies TGF-beta Signaling as a Key Regulator of Breast Cancer Morphology and Aggressiveness.
    Cancer Res. 2025 Apr 30. doi: 10.1158/0008-5472.CAN-24-2022.
    PubMed     Abstract available
    
    
    
65. SRIVASTAVA J, Yadav VK, Jimenez RV, Phadatare PR, et al
    Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS-Mutant Melanoma to MEK Inhibitors.
    Cancer Res. 2025 Apr 27. doi: 10.1158/0008-5472.CAN-24-0693.
    PubMed     Abstract available
    
    
    
66. SOUTO EP, Gong P, Landua JD, Rajaram Srinivasan R, et al
    Lineage Tracing and Single-Cell RNA Sequencing Reveal a Common Transcriptional State in Breast Cancer Tumor-Initiating Cells Characterized by IFN/STAT1 Activity.
    Cancer Res. 2025;85:1390-1409.
    PubMed     Abstract available
    
    
    
67. DOMMER AP, Kumarasamy V, Wang J, O'Connor TN, et al
    Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222.
    Cancer Res. 2025;85:1310-1326.
    PubMed     Abstract available
    
    
    March 2025
68. SCORTEGAGNA M, Murad R, Bina P, Feng Y, et al
    Age-Associated Modulation of TREM1/2-Expressing Macrophages Promotes Melanoma Progression and Metastasis.
    Cancer Res. 2025 Mar 24. doi: 10.1158/0008-5472.CAN-24-4317.
    PubMed     Abstract available
    
    
    
69. PEDRETTI F, Abdalfttah M, Pellegrino B, Mateo F, et al
    Harnessing STING Signaling and Natural Killer Cells overcomes PARP Inhibitor Resistance in Homologous Recombination Deficient Breast Cancer.
    Cancer Res. 2025 Mar 11. doi: 10.1158/0008-5472.CAN-24-2531.
    PubMed     Abstract available
    
    
    
70. MAHURON KM, Shahid O, Sao P, Wu C, et al
    Single Cell Analyses Reveal a Functionally Heterogeneous Exhausted CD8+ T Cell Subpopulation that is Correlated with Response to Checkpoint Therapy in Melanoma.
    Cancer Res. 2025 Mar 5. doi: 10.1158/0008-5472.CAN-23-3918.
    PubMed     Abstract available
    
    
    
71. OSPINA OE, Manjarres-Betancur R, Gonzalez-Calderon G, Soupir AC, et al
    spatialGE Is a User-Friendly Web Application That Facilitates Spatial Transcriptomics Data Analysis.
    Cancer Res. 2025;85:848-858.
    PubMed     Abstract available
    
    
    February 2025
72. SUN Z, Li Z, Wei Y, Xu L, et al
    SMARCA4 Inhibits Breast Cancer Progression and Metastasis through RHOA Suppression.
    Cancer Res. 2025 Feb 24. doi: 10.1158/0008-5472.CAN-24-2801.
    PubMed     Abstract available
    
    
    
73. BADO IL
    Deterministic Role of FOXF2 in Organ-Specific Macrometastasis Transition.
    Cancer Res. 2025;85:639-641.
    PubMed     Abstract available
    
    
    
74. ZHOU S, Zhang Y, Belmar J, Hou C, et al
    Stabilization of RUNX1 Induced by O-GlcNAcylation Promotes PDGF-BB-Mediated Resistance to CDK4/6 Inhibitors in Breast Cancer.
    Cancer Res. 2025 Feb 12. doi: 10.1158/0008-5472.CAN-24-2492.
    PubMed     Abstract available
    
    
    
75. IPPOLITOV D, Lin YH, Spence J, Glogowska A, et al
    The Brain-Penetrant Pan ErbB Inhibitor Poziotinib Effectively Targets HER2+ Breast Cancer Brain Metastases.
    Cancer Res. 2025 Feb 11. doi: 10.1158/0008-5472.CAN-24-1793.
    PubMed     Abstract available
    
    
    
76. METGE BJ, Williams L, Swain CA, Hinshaw DC, et al
    Ribosomal RNA Biosynthesis Functionally Programs Tumor-Associated Macrophages to Support Breast Cancer Progression.
    Cancer Res. 2025 Feb 4. doi: 10.1158/0008-5472.CAN-24-0707.
    PubMed     Abstract available
    
    
    
77. MADORSKY ROWDO FP, Martini R, Ackermann SE, Tang CP, et al
    Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition.
    Cancer Res. 2025;85:551-566.
    PubMed     Abstract available
    
    
    
78. TREMBATH HE, Spanheimer PM
    In Search of Representative Translational Cancer Model Systems.
    Cancer Res. 2025;85:407-409.
    PubMed     Abstract available
    
    
    January 2025
79. DEY P, Brisken C
    Breaking the Rhythm: Harnessing the Menstrual Cycle for Better Chemotherapy.
    Cancer Res. 2025 Jan 29. doi: 10.1158/0008-5472.CAN-25-0335.
    PubMed     Abstract available
    
    
    
80. VAN ALSTEN SC, Love MI, Calhoun BC, Butler EN, et al
    Genomic Analysis Reveals Racial and Age-Related Differences in the Somatic Landscape of Breast Cancer and the Association with Socioeconomic Factors.
    Cancer Res. 2025 Jan 29. doi: 10.1158/0008-5472.CAN-24-1788.
    PubMed     Abstract available
    
    
    
81. TABET I, Orhan E, Candiello E, Fenou L, et al
    Replication-Poison Treatment in BRCA1-Deficient Breast Cancer Causes MRE11 Over-Resection that Induces Single-Stranded DNA Accumulation and Mitotic Catastrophe.
    Cancer Res. 2025 Jan 29. doi: 10.1158/0008-5472.CAN-24-1404.
    PubMed     Abstract available
    
    
    
82. VISAL TH, Bayraktar R, den Hollander P, Attathikhun MA, et al
    Accumulation of CD38 in Hybrid Epithelial/Mesenchymal Cells Promotes Immune Remodeling and Metastasis in Breast Cancer.
    Cancer Res. 2025 Jan 24:OF1-OF18. doi: 10.1158/0008-5472.CAN-24-0400.
    PubMed     Abstract available
    
    
    
83. GAO L, Huang J, Xia J, Zhao P, et al
    SNHG17 Reprograms Energy Metabolism of Breast Cancer by Activating Mitochondrial DNAs Transcription.
    Cancer Res. 2025 Jan 22. doi: 10.1158/0008-5472.CAN-24-1271.
    PubMed     Abstract available
    
    
    
84. PIERRO EW, Cottam MA, An H, Lehmann BD, et al
    Comparison of Lean, Obese, and Weight Loss Models Reveals TREM2 Deficiency Attenuates Breast Cancer Growth Uniquely in Lean Mice and Alters Clonal T Cell Populations.
    Cancer Res. 2025 Jan 22. doi: 10.1158/0008-5472.CAN-24-3511.
    PubMed     Abstract available
    
    
    
85. TAU S, Chamberlin MD, Yang H, Marotti JD, et al
    Oxidative Phosphorylation is a Metabolic Vulnerability of Endocrine Therapy-Tolerant Persister Cells in ER+ Breast Cancer.
    Cancer Res. 2025 Jan 9. doi: 10.1158/0008-5472.CAN-24-1204.
    PubMed     Abstract available
    
    
    December 2024
86. CHEN SY, He PL, Lu LY, Lin MC, et al
    ST6GAL1-Mediated Sialylation of PECAM-1 Promotes a Transcellular Diapedesis-Like Process that Directs Lung Tropism of Metastatic Breast Cancer.
    Cancer Res. 2024 Dec 30. doi: 10.1158/0008-5472.CAN-24-1550.
    PubMed     Abstract available
    
    
    
87. RUBINSTEIN JC, Domanskyi S, Sheridan TB, Sanderson B, et al
    Spatiotemporal Profiling Defines Persistence and Resistance Dynamics During Targeted Treatment of Melanoma.
    Cancer Res. 2024 Dec 19. doi: 10.1158/0008-5472.CAN-24-0690.
    PubMed     Abstract available
    
    
    
88. NASCENTES MELO LM, Sabatier M, Ramesh V, Szylo KJ, et al
    Selenoprotein O Promotes Melanoma Metastasis and Regulates Mitochondrial Complex II Activity.
    Cancer Res. 2024 Dec 19. doi: 10.1158/0008-5472.CAN-23-2194.
    PubMed     Abstract available
    
    
    
89. FENG JR, Li X, Han C, Chang Y, et al
    C-Reactive Protein Induces Immunosuppression by Activating FcgammaR2B in Pulmonary Macrophages to Promote Lung Metastasis.
    Cancer Res. 2024;84:4184-4198.
    PubMed     Abstract available
    
    
    
90. SHI W, Li L, Zhao H, Li Z, et al
    Targeting SHCBP1 Inhibits Tumor Progression by Restoring Ciliogenesis in Ductal Carcinoma.
    Cancer Res. 2024;84:4156-4172.
    PubMed     Abstract available
    
    
    
91. BHAGWAT SV, Mur C, Vandekopple M, Zhao B, et al
    Imlunestrant is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wildtype and Mutant Breast Cancer.
    Cancer Res. 2024 Dec 9. doi: 10.1158/0008-5472.CAN-24-2608.
    PubMed     Abstract available
    
    
    
92. FORD CA, Koludrovic D, Centeno PP, Foth M, et al
    Targeting the PREX2/RAC1/PI3Kbeta Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma.
    Cancer Res. 2024 Dec 5. doi: 10.1158/0008-5472.CAN-23-2814.
    PubMed     Abstract available
    
    
    
93. FRIELING JS, Lynch CC
    Tales of Cancer-Induced Bone Disease from the Senescent Osteocyte Crypt.
    Cancer Res. 2024;84:3917-3918.
    PubMed     Abstract available
    
    
    November 2024
94. JIANG WJ, Zhou TH, Huang HJ, Li LS, et al
    Breast Cancer Subtype-Specific Organotropism is Dictated by FOXF2-Regulated Metastatic Dormancy and Recovery.
    Cancer Res. 2024 Nov 26. doi: 10.1158/0008-5472.CAN-24-0479.
    PubMed     Abstract available
    
    
    
95. ZENG W, Zhang R, Huang P, Chen M, et al
    Ferroptotic Neutrophils Induce Immunosuppression and Chemoresistance in Breast Cancer.
    Cancer Res. 2024 Nov 12. doi: 10.1158/0008-5472.CAN-24-1941.
    PubMed     Abstract available
    
    
    
96. IZAR B, Kim M
    Peritumoral Venous Vessels: Autobahn and Portal for T cells to Melanoma Brain Metastasis.
    Cancer Res. 2024 Nov 8. doi: 10.1158/0008-5472.CAN-24-4054.
    PubMed     Abstract available
    
    
    
97. SHEA A, Eyal-Lubling Y, Guerrero-Romero D, Manzano Garcia R, et al
    Modeling Drug Responses and Evolutionary Dynamics using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple Negative Breast Cancer.
    Cancer Res. 2024 Nov 8. doi: 10.1158/0008-5472.CAN-24-1703.
    PubMed     Abstract available
    
    
    
98. JASANI N, Xu X, Posorske B, Kim Y, et al
    PHGDH Induction by MAPK is Essential for Melanoma Formation and Creates an Actionable Metabolic Vulnerability.
    Cancer Res. 2024 Nov 4. doi: 10.1158/0008-5472.CAN-24-2471.
    PubMed     Abstract available
    
    
    October 2024
99. KUETT L, Bollhagen A, Tietscher S, Sobottka B, et al
    Distant Metastases of Breast Cancer Resemble Primary Tumors in Cancer Cell Composition but Differ in Immune Cell Phenotypes.
    Cancer Res. 2024 Oct 22. doi: 10.1158/0008-5472.CAN-24-1211.
    PubMed     Abstract available
    
    
    
100. CACKOWSKI FC, Korkaya H
     Breast Cancer Disseminated Tumor Cells: Do They Stay and Fight or Run and Hide?
     Cancer Res. 2024;84:3319-3321.
     PubMed     Abstract available
     
     
     
101. PAREJA F, Dopeso H, Wang YK, Gazzo AM, et al
     A Genomics-Driven Artificial Intelligence-Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms.
     Cancer Res. 2024;84:3478-3489.
     PubMed     Abstract available
     
     
     
102. FALCONE M, Salhia B, Hughes Halbert C, Roussos Torres ET, et al
     Impact of Structural Racism and Social Determinants of Health on Disparities in Breast Cancer Mortality.
     Cancer Res. 2024 Oct 2. doi: 10.1158/0008-5472.CAN-24-1359.
     PubMed     Abstract available
     
     
     
103. GEMMA C, Lai CF, Singh AK, Belfiore A, et al
     Induction of the TEAD Co-activator VGLL1 by Estrogen Receptor-Targeted Therapy Drives Resistance in Breast Cancer.
     Cancer Res. 2024 Oct 2. doi: 10.1158/0008-5472.CAN-24-0013.
     PubMed     Abstract available
     
     
     
104. BOUKERCHE H, Su ZZ, Emdad L, Sarkar D, et al
     Retraction: mda-9/Syntenin Regulates the Metastatic Phenotype in Human Melanoma Cells by Activating Nuclear Factor-kappaB.
     Cancer Res. 2024;84:3312.
     PubMed    
     
     
     
105. PURDY SC, Ford HL
     Remembering Hypoxia: Uncovering the Long-Term Effects of Transient Oxygen Deprivation on IFN Signaling and Progression of Breast Cancer.
     Cancer Res. 2024;84:3125-3127.
     PubMed     Abstract available
     
     
     
106. SHIN SY, Chew NJ, Ghomlaghi M, Chueh AC, et al
     Integrative Modeling of Signaling Network Dynamics Identifies Cell Type-Selective Therapeutic Strategies for FGFR4-Driven Cancers.
     Cancer Res. 2024;84:3296-3309.
     PubMed     Abstract available
     
     
     
107. GONZALEZ ME, Brophy B, Eido A, Leonetti AE, et al
     CCN6 Suppresses Metaplastic Breast Carcinoma by Antagonizing Wnt/beta-Catenin Signaling to Inhibit EZH2-Driven EMT.
     Cancer Res. 2024;84:3235-3249.
     PubMed     Abstract available
     
     
     September 2024
108. LI Y, Ming R, Zhang T, Gao Z, et al
     TCTN1 Induces Fatty Acid Oxidation to Promote Melanoma Metastasis.
     Cancer Res. 2024 Sep 26. doi: 10.1158/0008-5472.CAN-24-0158.
     PubMed     Abstract available
     
     
     
109. KAUR J, Adhikari M, Sabol HM, Anloague A, et al
     Single-cell Transcriptomic Analysis Identifies Senescent Osteocytes that Trigger Bone Destruction in Breast Cancer Metastasis.
     Cancer Res. 2024 Sep 23. doi: 10.1158/0008-5472.CAN-24-0857.
     PubMed     Abstract available
     
     
     
110. LUO M, Shen N, Shang L, Fang Z, et al
     Simultaneous Targeting of NQO1 and SOD1 Eradicates Breast Cancer Stem Cells via Mitochondrial Futile Redox Cycling.
     Cancer Res. 2024 Sep 12. doi: 10.1158/0008-5472.CAN-24-0800.
     PubMed     Abstract available
     
     
     
111. OKADA M, Yamasaki S, Nakazato H, Hirahara Y, et al
     ARID1A-Deficient Tumors Acquire Immunogenic Neoantigens during the Development of Resistance to Targeted Therapy.
     Cancer Res. 2024;84:2792-2805.
     PubMed     Abstract available
     
     
     
112. CONNER SJ, Borges HB, Guarin JR, Gerton TJ, et al
     Obesity Induces Temporally Regulated Alterations in the Extracellular Matrix That Drive Breast Tumor Invasion and Metastasis.
     Cancer Res. 2024;84:2761-2775.
     PubMed     Abstract available
     
     
     August 2024
113. LI YW, Dai LJ, Wu XR, Zhao S, et al
     Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies.
     Cancer Res. 2024 Aug 26. doi: 10.1158/0008-5472.CAN-23-4066.
     PubMed     Abstract available
     
     
     
114. LEWIS MW, King CM, Wisniewska K, Regner MJ, et al
     CRISPR Screening of Transcribed Super-Enhancers Identifies Drivers of Triple-Negative Breast Cancer Progression.
     Cancer Res. 2024 Aug 26. doi: 10.1158/0008-5472.CAN-23-3995.
     PubMed     Abstract available
     
     
     
115. ZHOU Z, Si Y, Zhang J, Chen K, et al
     A Dual-Payload Antibody-Drug Conjugate Targeting CD276/B7-H3 Elicits Cytotoxicity and Immune Activation in Triple-Negative Breast Cancer.
     Cancer Res. 2024 Aug 26. doi: 10.1158/0008-5472.CAN-23-4099.
     PubMed     Abstract available
     
     
     
116. LI M, Lulla AR, Wang Y, Tsavachidis S, et al
     Low Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer.
     Cancer Res. 2024 Aug 26. doi: 10.1158/0008-5472.CAN-23-4130.
     PubMed     Abstract available
     
     
     
117. HEATH J, Mirabelli C, Annis MG, Sabourin V, et al
     The Neurodevelopmental Protein POGZ Suppresses Metastasis in Triple Negative Breast Cancer by Attenuating TGFbeta Signaling.
     Cancer Res. 2024 Aug 13. doi: 10.1158/0008-5472.CAN-23-3887.
     PubMed     Abstract available
     
     
     
118. BUSHNELL GG, Sharma D, Wilmot HC, Zheng M, et al
     Natural Killer Cell Regulation of Breast Cancer Stem Cells Mediates Metastatic Dormancy.
     Cancer Res. 2024 Aug 6. doi: 10.1158/0008-5472.CAN-24-0030.
     PubMed     Abstract available
     
     
     July 2024
119. WANG X, Qu Y, Xu Q, Jiang Z, et al
     NQO1 Triggers Neutrophil Recruitment and NET formation to Drive Lung Metastasis of Invasive Breast Cancer.
     Cancer Res. 2024 Jul 29. doi: 10.1158/0008-5472.CAN-24-0291.
     PubMed     Abstract available
     
     
     
120. HSU WJ, Chiang MC, Chao YC, Chang YC, et al
     Arginine methylation of DDX3 by PRMT1 mediates mitochondrial homeostasis to promote breast cancer metastasis.
     Cancer Res. 2024 Jul 23. doi: 10.1158/0008-5472.CAN-23-3829.
     PubMed     Abstract available
     
     
     
121. HUANG YZ, Sang MY, Xi PW, Xu RX, et al
     FANCI Inhibition Induces PARP1 Redistribution to Enhance the Efficacy of PARP Inhibitors in Breast Cancer.
     Cancer Res. 2024 Jul 22. doi: 10.1158/0008-5472.CAN-23-2738.
     PubMed     Abstract available
     
     
     
122. PIEMONTE KM, Ingles NN, Weber Bonk KL, Valentine MJ, et al
     Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer.
     Cancer Res. 2024 Jul 22. doi: 10.1158/0008-5472.CAN-23-2558.
     PubMed     Abstract available
     
     
     
123. HILLIS AL, Martin TD, Manchester HE, Hogstrom J, et al
     Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast Cancer.
     Cancer Res. 2024 Jul 18. doi: 10.1158/0008-5472.CAN-24-0970.
     PubMed     Abstract available
     
     
     
124. IRIONDO O, Mecenas D, Li Y, Chin CR, et al
     Hypoxic Memory Mediates Prolonged Tumor Intrinsic Type I Interferon Suppression to Promote Breast Cancer Progression.
     Cancer Res. 2024 Jul 11. doi: 10.1158/0008-5472.CAN-23-2028.
     PubMed     Abstract available
     
     
     
125. LEE G, Wong C, Cho A, West JJ, et al
     E-cadherin Induces Serine Synthesis to Support Progression and Metastasis of Breast Cancer.
     Cancer Res. 2024 Jul 3. doi: 10.1158/0008-5472.CAN-23-3082.
     PubMed     Abstract available
     
     
     
126. ENRIQUEZ JA, Mittelbrunn M
     Warburg Effect Reshapes Tumor Immunogenicity.
     Cancer Res. 2024;84:2043-2045.
     PubMed     Abstract available
     
     
     June 2024
127. MENEGOLLO M, Bentham RB, Henriques T, Ng SQ, et al
     Multi-State Gene Cluster Switches Determine the Adaptive Mitochondrial And Metabolic Landscape of Breast Cancer.
     Cancer Res. 2024 Jun 26. doi: 10.1158/0008-5472.CAN-23-3172.
     PubMed     Abstract available
     
     
     
128. XU G, Huang R, Wumaier R, Lyu J, et al
     Proteomic Profiling of Serum Extracellular Vesicles Identifies Diagnostic Signatures and Therapeutic Targets in Breast Cancer.
     Cancer Res. 2024 Jun 20. doi: 10.1158/0008-5472.CAN-23-3998.
     PubMed     Abstract available
     
     
     
129. OATMAN N, Gawali MV, Congrove S, Caceres R, et al
     A multimodal drug-diet-immunotherapy combination restrains melanoma progression and metastasis.
     Cancer Res. 2024 Jun 17. doi: 10.1158/0008-5472.CAN-23-1635.
     PubMed     Abstract available
     
     
     
130. ELEMENTO O
     How Artificial Intelligence Unravels the Complex Web of Cancer Drug Response.
     Cancer Res. 2024;84:1745-1746.
     PubMed     Abstract available
     
     
     
131. SUN X, Verma SP, Jia G, Wang X, et al
     Case-Case Genome-Wide Analyses Identify Subtype-Informative Variants that Confer Risk for Breast Cancer.
     Cancer Res. 2024 Jun 4. doi: 10.1158/0008-5472.CAN-23-3854.
     PubMed     Abstract available
     
     
     
132. TUCKER JB, Carlsen CL, Scribano CM, Pattaswamy SM, et al
     CENP-E inhibition induces chromosomal instability and synergizes with diverse microtubule-targeting agents in breast cancer.
     Cancer Res. 2024 Jun 4. doi: 10.1158/0008-5472.CAN-23-3332.
     PubMed     Abstract available
     
     
     May 2024
133. HUANG MY, Hu SY, Dong J, Deng L, et al
     The DRAP1/DR1 Repressor Complex Increases mTOR Activity to Promote Progression and Confer Everolimus Sensitivity in Triple-Negative Breast Cancer.
     Cancer Res. 2024 May 15. doi: 10.1158/0008-5472.CAN-23-2781.
     PubMed     Abstract available
     
     
     
134. LIU D, Wei B, Liang L, Sheng Y, et al
     The Circadian Clock Component RORA Increases Immunosurveillance in Melanoma by Inhibiting PD-L1 Expression.
     Cancer Res. 2024 May 8. doi: 10.1158/0008-5472.CAN-23-3942.
     PubMed     Abstract available
     
     
     April 2024
135. XIA J, Zhang L, Peng X, Tu J, et al
     IL1R2 blockade alleviates immunosuppression and potentiates anti-PD-1 efficacy in triple-negative breast cancer.
     Cancer Res. 2024 Apr 24. doi: 10.1158/0008-5472.CAN-23-3429.
     PubMed     Abstract available
     
     
     
136. ZHENG SM, Feng YC, Zhu Q, Li RQ, et al
     MILIP Binding to tRNAs Promotes Protein Synthesis to Drive Triple-Negative Breast Cancer.
     Cancer Res. 2024 Apr 9:OF1-OF15. doi: 10.1158/0008-5472.CAN-23-3046.
     PubMed     Abstract available
     
     
     
137. FRITSCH EF, Ott PA
     Personalized Cancer Vaccines Directed against Tumor Mutations: Building Evidence from Mice to Humans.
     Cancer Res. 2024;84:953-955.
     PubMed     Abstract available
     
     
     March 2024
138. ZHANG M, Zhou K, Wang Z, Liu T, et al
     A subpopulation of luminal progenitors secretes pleiotrophin to promote angiogenesis and metastasis in inflammatory breast cancer.
     Cancer Res. 2024 Mar 20. doi: 10.1158/0008-5472.CAN-23-2640.
     PubMed     Abstract available
     
     
     
139. QIU Y, Wang X, Sun Y, Jin T, et al
     ACSL4-mediated membrane phospholipid remodeling induces integrin beta1 activation to facilitate triple-negative breast cancer metastasis.
     Cancer Res. 2024 Mar 12. doi: 10.1158/0008-5472.CAN-23-2491.
     PubMed     Abstract available
     
     
     February 2024
140. YAMAMOTO T, Hayashida T, Masugi Y, Oshikawa K, et al
     PRMT1 sustains de novo fatty acid synthesis by methylating PHGDH to drive chemoresistance in triple-negative breast cancer.
     Cancer Res. 2024 Feb 22. doi: 10.1158/0008-5472.CAN-23-2266.
     PubMed     Abstract available
     
     
     
141. YAN L, Wu M, Wang T, Yuan H, et al
     Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming that Drives Immune Evasion.
     Cancer Res. 2024 Feb 9. doi: 10.1158/0008-5472.CAN-23-2390.
     PubMed     Abstract available
     
     
     
142. BERNARD MJ, Goldstein AS
     A metabolic-epigenetic mechanism directs cell fate and therapeutic sensitivity in breast cancer.
     Cancer Res. 2024 Feb 8. doi: 10.1158/0008-5472.CAN-24-0460.
     PubMed     Abstract available
     
     
     
143. GEDIK ME, Saatci O, Oberholtzer N, Uner M, et al
     Targeting TACC3 induces immunogenic cell death and enhances T-DM1 response in HER2-positive breast cancer.
     Cancer Res. 2024 Feb 6. doi: 10.1158/0008-5472.CAN-23-2812.
     PubMed     Abstract available
     
     
     January 2024
144. MARQUEZ-PALENCIA M, Reza Herrera L, Parida PK, Ghosh S, et al
     AXL/WRNIP1 mediates replication stress response and promotes therapy resistance and metachronous metastasis in HER2+ breast cancer.
     Cancer Res. 2024 Jan 8. doi: 10.1158/0008-5472.CAN-23-1459.
     PubMed     Abstract available
     
     
     October 2023
145. YU S, Wang Y, Gong X, Fan Z, et al
     LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity.
     Cancer Res. 2023;83:3220-3236.
     PubMed     Abstract available
     
     
     August 2023
146. COHEN N, Mundhe D, Deasy SK, Adler O, et al
     Breast cancer-secreted factors promote lung metastasis by signaling systemically to induce a fibrotic pre-metastatic niche.
     Cancer Res. 2023 Aug 7:CAN-22-3707. doi: 10.1158/0008-5472.CAN-22-3707.
     PubMed     Abstract available
     
     
     
147. AMAYA RAMIREZ CC, Loayza-Puch F
     Breast Cancer Metastatic Progression Requires mRNA Posttranscriptional Suppression.
     Cancer Res. 2023;83:2448-2449.
     PubMed     Abstract available
     
     
     July 2023
148. WANG Z, Zhang N, Zhang M, Jiang Y, et al
     GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner.
     Cancer Res. 2023 Jul 18:CAN-22-3471. doi: 10.1158/0008-5472.CAN-22-3471.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Dermatology is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum